Emergent Biosolutions, Inc. (EBS): Price and Financial Metrics
Emergent Biosolutions, Inc. (EBS)
Today's Latest Price: $51.22 USD
Updated Mar 27 6:40pm
Add EBS to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
EBS Stock Summary
- With a one year PEG ratio of 199.86, Emergent BioSolutions Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 86.08% of US stocks.
- EBS's current price/earnings ratio is 53.35, which is higher than 91.41% of US stocks with positive earnings.
- Revenue growth over the past 12 months for Emergent BioSolutions Inc comes in at 41.36%, a number that bests 87.2% of the US stocks we're tracking.
- If you're looking for stocks that are quantitatively similar to Emergent BioSolutions Inc, a group of peers worth examining would be ON, CSGS, CIEN, AVAV, and AEIS.
- Visit EBS's SEC page to see the company's official filings. To visit the company's web site, go to www.emergentbiosolutions.com.
EBS Stock Price Chart More Charts
EBS Price/Volume Stats
| Current price | $51.22 | 52-week high | $71.19 |
| Prev. close | $57.34 | 52-week low | $39.11 |
| Day low | $51.00 | Volume | 488,500 |
| Day high | $56.94 | Avg. volume | 453,258 |
| 50-day MA | $58.22 | Dividend yield | N/A |
| 200-day MA | $52.34 | Market Cap | 2.66B |
Emergent Biosolutions, Inc. (EBS) Company Bio
Emergent BioSolutions is a biopharmaceutical company which develops, manufactures, and delivers a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases. The company was founded in 1998 and is based in Gaithersburg, Maryland.
EBS Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $51.22 | $47.14 | -8% |
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Emergent BioSolutions Inc. To summarize, we found that Emergent BioSolutions Inc ranked in the 39th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. The most interesting components of our discounted cash flow analysis for Emergent BioSolutions Inc ended up being:
- Its compound free cash flow growth rate, as measured over the past 5.79 years, is 0.21% -- higher than 67.86% of stocks in our DCF forecasting set.
- Emergent BioSolutions Inc's effective tax rate, as measured by taxes paid relative to net income, is at 17 -- greater than 65.52% of US stocks with positive free cash flow.
- Relative to other stocks in its sector (Healthcare), Emergent BioSolutions Inc has a reliance on debt greater than 60.26% of them.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -10% |
| 1% | -9% |
| 2% | -8% |
| 3% | -7% |
| 4% | -6% |
| 5% | -5% |
Want more companies with a valuation profile/forecast similar to that of Emergent BioSolutions Inc? See VIVO, ADMT, NUVA, PBH, and MD.
Top Stories View All
Top 4 Home Improvement Stocks with Stimulus Checks on the Way
Rip Your Face Off Rally!
Best & Worst Performing Stock Industries for March 27, 2020
Best & Worst Performing Small Cap Stocks for March 27, 2020
Best & Worst Performing Mid Cap Stocks for March 27, 2020
View All Top Stories
Loading social stream, please wait...